Nucleic Acids

Chaired By:

Lawrence C. Thompson, PhD
Pfizer, Inc.


  • Starting Materials / Cell-Free Synthesis
  • Identification of Topological Variations
  • Cross-Contamination
  • Inverted Terminal Repeat (ITR) Stability
  • Next-Gen Sequencing for Contaminants
  • R&D vs GMP-Like vs cGMP
  • Characterization and Comparability
  • Clarification / Purification / Filtration
  • Process and Method Validation
  • Regulatory Issues

Sponsored By

Exhibits By

Additional Support By